Abstract:Since the time of Rudolf Virchow in the 19th century, it has been well-known that cancer-associated inflammation contributes to tumor initiation and progression. However, it remains unclear whether a collapse of the balance between the antitumor immune response via the immunological surveillance system and protumor immunity due to cancer-related inflammation is responsible for cancer malignancy. The majority of inflammatory signals affect tumorigenesis by activating signal transducer and activation of transcription 3 (STAT3) and nuclear factor-κB. Persistent STAT3 activation in malignant cancer cells mediates extremely widespread functions, including cell growth, survival, angiogenesis, and invasion and contributes to an increase in inflammation-associated tumorigenesis. In addition, intracellular STAT3 activation in immune cells causes suppressive effects on antitumor immunity and leads to the differentiation and mobilization of immature myeloid-derived cells and tumor-associated macrophages. In many cancer types, STAT3 does not directly rely on its activation by oncogenic mutations but has important oncogenic and malignant transformation-associated functions in both cancer and stromal cells in the tumor microenvironment (TME). We have reported a series of studies aiming towards understanding the molecular mechanisms underlying the proliferation of various types of tumors involving signal-transducing adaptor protein-2 as an adaptor molecule that modulates STAT3 activity, and we recently found that AT-rich interactive domain-containing protein 5a functions as an mRNA stabilizer that orchestrates an immunosuppressive TME in malignant mesenchymal tumors. In this review, we summarize recent advances in our understanding of the functional role of STAT3 in tumor progression and introduce novel molecular mechanisms of cancer development and malignant transformation involving STAT3 activation that we have identified to date. Finally, we discuss potential therapeutic strategies for cancer that target the signaling pathway to augment STAT3 activity.

Research Progress in Multiple Regulation Pathways of STAT3 in Cancer

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Data from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

STAT3 Pathway in Cancers: Past, Present, and Future.

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Novel activators and small-molecule inhibitors of STAT3 in cancer

Stat3-regulated Genes and Advances on Tumor Researches

The regulatory relationship between transcription factor STAT3 and noncoding RNA

Role of STAT3 in cancer cell epithelial‐mesenchymal transition (Review)

STAT3: The Key Player in The Network of Inflammation and Cancer

Targeting STAT3 in Cancer Immunotherapy

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance

Role of STAT3 signaling pathway in breast cancer

Constitutive activation of STAT3 in breast cancer cells: A review

The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy

Evaluation of potential Stat3-regulated genes in human breast cancer

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation

Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression

The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy